HomeInvesting NewsStock in Shuttle Pharmaceuticals Fell 75% After Rising 545% After Its $10...

Stock in Shuttle Pharmaceuticals Fell 75% After Rising 545% After Its $10 Million IPO

Published on

Sensitizers from Shuttle Pharmaceuticals’ (NASDAQ:SHPH) are created to answer the critical clinical need to enhance the outcomes of cancer patients receiving radiation therapy while lowering adverse effects.

Shuttle Pharmaceuticals’ (NASDAQ:SHPH) 

Shuttle Pharmaceuticals’ (NASDAQ:SHPH) stock, which went public on Wednesday with a $10 million IPO, fell 75% in late-morning trading on Friday after rising 545% in the previous two days.

Shuttle stock hit a low of $12.63 late in the morning after opening at $34.35. At around 11:25 a.m. ET, the stock was recently traded for $13.11, a 75% decrease from Thursday’s close.

On Wednesday, Shuttle issued 1.23 million units at a price of $8.125 each. Each unit contained one share and a warrant to purchase an additional share for $0.01 per share. The stock shot up 373% on its first day on the market, closing at $38.48, and then another 36% on Thursday, closing at $52.40.

Located in Maryland, the company has been developing remedies to improve the efficiency of radiation treatments for cancer.

Read “Shuttle Pharmaceuticals Targets $14 Million IPO for Radiation Therapy Enhancement” by SA contributor Donovan Jones for a more thorough analysis of the company.

Future plans

With its platform of sensitizers, Shuttle Pharma has access to a variety of product candidates that are intended to address both the urgent clinical need and the present drawbacks of combining “off-label” medications with prospective novel sensitizer agents. The primary clinical sensitizer drug candidate, ripoxuridine, can sensitize quickly proliferating cancer cells, and selective histone deacetylase (HDAC) inhibitors can sensitize cancer cells and activate the immune system. Both standard X-ray and proton radiation therapy, as well as immune therapies, will be evaluated in conjunction with our cutting-edge technology. Ropidoxuridine has already finished a Phase I clinical trial. In preclinical models of solid tumor malignancies, our HDAC inhibitor platform therapeutic candidates have been examined.

For the company’s Nasdaq IPO, Valuable Capital Ltd. served as co-underwriter, and Boustead Securities, LLC served as lead underwriter.

Featured Image – DepositPhoto © Alexraths

See Disclaimer Please

Latest News

AT&T Stock is Going Up After a Few Bad Years

Nearing the end of a year-long change is AT&T stock. By eliminating its entertainment...

Which is Better: Bitcoin Stock or Ethereum Stock?

A cryptocurrency is a secure, virtual currency that is nearly impossible to counterfeit. Ethereum...

Nio (Nio Stock), BYD, and Other Chinese EV Manufacturers Expand Into Europe

Chinese buyers were won over by Nio (NYSE:NIO) and BYD (BYDDF) for their svelte,...

Facebook (META Stock) Claims To Have Removed A Chinese-Based Propaganda Effort Aimed Against The Midterm Elections In The United States

Before the November midterm elections, Meta Platforms Inc (NASDAQ:META) said on Tuesday that it...

More like this

QuantumScape Stock: Reasons for Today’s Spike

QuantumScape Stock (NYSE:QS) EV Battery company QuantumScape's stock price gained by 5% on Tuesday morning....

Roblox Stock (RBLX) Rises Despite Market Declines: Here’s What You Need to Know

Roblox stock (NYSE:RBLX) reached a price of $35.55 before calling it a day on...

Why Apple Stock Was Rising When the Market Opened This Morning

Apple Stock (NASDAQ:AAPL) Apple stock opened Tuesday's trading session up 2.6%, but the Apple stock...

Today’s 3% Rise in Coinbase Stock Is Just the Beginning.

Coinbase Stock (NASDAQ:COIN) Coinbase stock has risen by 3%, making it the best-performing cryptocurrency exchange...

Activision Stock (ATVI) Drops -0.83%: What You Should Know

The most recent trading session ended with Activision stock (NASDAQ:ATVI) reaching a price of...

TSLA Stock Is Expected to Break a Record With Q3 Deliveries

TSLA stock was trading at $279.06 as of 02:31 PM EDT. Tesla (NASDAQ:TSLA) is asking...